BACKGROUND: The recent introduction of the depot somatostatin analogues octreotide LAR and lanreotide represent major advances in the medical treatment of acromegaly. However, it is uncertain whether the recommended dose intervals of 4 weeks and 10-14 days, respectively, are applicable to all patients. AIMS: To determine the optimum intervals between depot injections of either octreotide LAR and lanreotide for the suppression of serum GH and IGF-I in patients with acromegaly. Twenty-seven pat...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record